Jump Financial LLC Purchases New Position in United Therapeutics Co. (NASDAQ:UTHR)

Jump Financial LLC purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,046 shares of the biotechnology company's stock, valued at approximately $369,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Signaturefd LLC boosted its holdings in shares of United Therapeutics by 4.7% in the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after buying an additional 30 shares during the last quarter. Parallel Advisors LLC lifted its stake in United Therapeutics by 2.8% in the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after acquiring an additional 30 shares during the last quarter. Anchor Investment Management LLC grew its position in shares of United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after acquiring an additional 30 shares during the period. Great Lakes Advisors LLC raised its holdings in shares of United Therapeutics by 1.6% in the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after purchasing an additional 31 shares during the period. Finally, Oregon Public Employees Retirement Fund lifted its stake in United Therapeutics by 0.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after purchasing an additional 33 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares in the company, valued at $2,703,424. The trade was a 22.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 74,500 shares of company stock valued at $24,472,050. 11.90% of the stock is currently owned by insiders.

United Therapeutics Stock Performance

Shares of UTHR traded down $0.92 during mid-day trading on Thursday, reaching $302.18. 95,126 shares of the company were exchanged, compared to its average volume of 447,518. The business has a 50 day simple moving average of $304.50 and a two-hundred day simple moving average of $345.39. United Therapeutics Co. has a 52 week low of $236.65 and a 52 week high of $417.82. The stock has a market capitalization of $13.57 billion, a PE ratio of 13.29, a PEG ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the previous year, the company earned $6.17 EPS. The company's revenue for the quarter was up 17.2% on a year-over-year basis. On average, analysts predict that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective for the company in a research report on Monday, April 21st. JPMorgan Chase & Co. lowered their price target on shares of United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th. Finally, HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $390.17.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.